Ingenol mebutate

Ingenol mebutate, also known as Picato, is a topical medication used to treat actinic keratosis (AK), a pre-cancerous skin condition. It is a P-glycoprotein inhibitor and works by killing the abnormal cells that make up AK lesions. It is available in a gel form and is applied to the affected area for two or three days. Ingenol mebutate is usually well tolerated, but may cause local skin reactions such as redness, swelling, and blistering.

Here's a breakdown of Ingenol mebutate:

What it is:

• Ingenol mebutate, previously sold under the brand name Picato, is a topical medication used to treat a specific skin condition.

Important to note:

• Discontinued production: As of October 2020, the manufacturer discontinued production due to safety concerns.

Previous Use:

• Treated actinic keratosis (AK): These are rough, scaly patches that develop on sun-exposed areas of the skin.
• Functioned as a cytotoxic agent: Worked by inducing cell death in the abnormal cells associated with AK.

Administration:

• Came in the form of a gel applied directly to the affected skin.
• Dosage and application schedule varied depending on the location and severity of AK.

Safety Information:

• Increased risk of skin cancer: Studies raised concerns about a potential link between Ingenol mebutate and an increased risk of non-melanoma skin cancer. This is why the medication was discontinued.

Disclaimer:

• Due to safety concerns and discontinued production, Ingenol mebutate is no longer a recommended treatment option for AK.
• It's crucial to consult a dermatologist or healthcare provider for diagnosis and treatment of actinic keratosis. They can recommend alternative medications and strategies suitable for your specific case.

Current Treatment Options:

• Several other topical medications and procedures are available for treating AK.
• A healthcare professional can advise on the most appropriate course of treatment based on individual needs.